Alentis Therapeutics, a biotech firm based in Switzerland, has successfully raised $181.4 million in a Series D financing round. The funding will be used for the clinical development of the company's antibody-drug conjugates (ADCs) that target claudin-1 (CLDN1)-positive tumors and organ fibrosis.
This focus on CLDN1 highlights Alentis's commitment to advancing therapeutic options in cancer and fibrotic diseases. Alentis CEO Roberto Iacone emphasized the transformative potential of CLDN1 ADCs for treating solid tumors. The company plans to deliver clinical data for its programs within the next twelve to eighteen months.
Alentis, founded in 2018, has completed multiple financing rounds and has raised a total of $366.4 million. The involvement of high-profile investors reflects confidence in the company's approach and the growing interest in biotechnology as an investment sector. The strategic partnerships formed through this financing will support Alentis's research and development efforts.
Chairman Luca Santarelli is optimistic about the future of Alentis and the funds raised will be instrumental in advancing the company's clinical trials and exploring the therapeutic applications of its ADCs. Alentis's focus on CLDN1-targeted therapies positions it at the forefront of a promising area of research in cancer treatment.